Thera-SAbDab

OTELIXIZUMAB

>   Structural Summary
TherapeuticOtelixizumab
TargetCD3E
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS
Light ChainDIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2007
INN Year Recommended2008
Companies InvolvedBTG, GlaxoSmithKline, Tolerx
Conditions Approvedna
Conditions ActiveType 1 diabetes mellitus
Conditions DiscontinuedGraves ophthalmopathy, Multiple sclerosis, Myasthenia gravis, Psoriasis, Psoriatic arthritis, Rheumatoid arthritis
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy